Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

SNSS $1.71 0.2800 +19.58%
ZIOP $3.24 0.4400 +15.71%
FATE $4.62 0.3900 +9.22%
TGTX $10.89 0.8400 +8.36%
ADXS $3.33 0.2500 +8.12%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMGN $8.75 -0.4700 -5.10%
AVEO $0.97 -0.0500 -4.90%
CVM $0.66 -0.0299 -4.33%
CERU $3.96 -0.1600 -3.88%
CYTR $2.80 -0.1100 -3.78%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

New Report: Past Drug Failures Help Create the War on Cancer's Next Successes

(PhRMA) Oct 7, 2014 - Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “Researching Cancer Medicines: Setbacks and Stepping Stones,” which highlights the number of investigational cancer medicines that did not succeed in clinical trials and how these so-called “failures” are a critical part of the drug development process.
read press release 

Nearly 800 New Medicines in Development to Help in the Fight Against Cancer

(PhRMA) Oct 6, 2014 - America’s biopharmaceutical research companies are currently developing nearly 800 new medicines and vaccines for cancer, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
read press release 

Ascension Health Bans Genentech Sales Reps After Losing Drug Discounts

( Oct 7, 2014 - A change in the supply chain for three important Genentech cancer medications elicits a strong reaction from one of the nation's largest operators of hospitals.
read article 

BrainStorm : FDA Grants Fast Track Designation To NurOwn For Treatment Of ALS

( Oct 7, 2014 - BrainStorm Cell Therapeutics Inc. said that the United States Food and Drug Administration or FDA has designated NurOwn as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease).
read article 

Sanofi Says It Told U.S. About Improper-Payment Claims

(Wall Street Journal) Oct 6, 2014 - Sanofi says it told U.S. authorities about allegations of improper payments to health-care professionals in the Mideast and East Africa, joining a lineup of pharmaceutical companies that have faced similar claims.
read article (paid subscription required) 

Bristol-Myers Pulls U.S. Marketing Application for Hepatitis C Treatment

(Reuters) Oct 7, 2014 - Bristol-Myers Squibb said it withdrew its U.S. marketing application for an oral drug combination to treat hepatitis C, citing a "rapidly evolving" treatment landscape in the country.
read article 

Why Extremely Expensive Drugs Are Often Worth the Cost

(Washington Post/Wonkblog) Oct 6, 2014 - A new study finds that new specialty drugs often provide substantially much higher health benefits than the traditional drugs, but the specialty drugs also come with significantly higher costs, according to research published in this month's Health Affairs journal.
read article (free registration required) 

Extra Scrutiny for Hospices

(New York Times/The New Old Age blog) Oct 6, 2014 - Bipartisan legislation, that increasingly rare phenomenon, will soon bring greater federal oversight to hospice programs across the country.
read article 

Merck KGaA Cancer Pact with ICR and Wellcome Trust

(PharmaTimes [UK]) Oct 7, 2014 - Merck KGaA is linking up with the Institute of Cancer Research and the Wellcome Trust to develop cancer treatments.
read article 

Advanced Cell Diagnostics Awarded $1.4 Million NCI Grant to Develop Ultrasensitive Diagnostic Test for B-Cell Lymphoma

(Yahoo! Finance) Oct 7, 2014 - Advanced Cell Diagnostics, Inc. has been awarded a $1.4 million grant from National Cancer Institute (NCI) under its SBIR Phase II Program to develop and validate a diagnostic test for discriminating various B-cell non-Hodgkin lymphomas (NHLs) from benign lymphoproliferative diseases.
read article 

NanoString Collaborates with Brigham and Women’s Hospital in Boston to Accelerate Translation of Genomic Discoveries into Clinical Diagnostics in Oncology

(NanoString Technologies) Oct 6, 2014 - NanoString Technologies, Inc. today announced that it has signed a multi-year, multi-investigator research collaboration with Harvard-affiliated Brigham and Women’s Hospital to accelerate the translation of genomic biomarker discoveries into clinical cancer diagnostics.
read corporate press release 

BIO Statement on 60 Minutes Cancer Drug Segment

( Oct 6, 2014 - The Biotechnology Industry Organization (BIO) released the following statement today in response to a misleading segment on the cost of innovative cancer therapies on this week’s 60 Minutes.
read press release 

ASCO Statement on 60 Minutes Story on Cancer Drug Costs

(ASCO in Action) Oct 6, 2014 - The American Society of Clinical Oncology (ASCO) commends 60 Minutes for highlighting the fast-rising costs of cancer drugs in its thought-provoking story, “The Eye Popping Cost of Cancer Drugs,” that aired on October 5, 2014.
read article 

‘Financial Toxicity:’ Who’s Really to Blame for High Cancer Drug Prices?

(Wall Street Journal/Pharmalot blog) Oct 7, 2014 - File this under ‘the blame game.’ The issue of expensive cancer drugs is hardly new, of course, but 60 Minutes aired a segment the other night that likely helped highlight the controversy for the mass audience that watches the popular news program.
read article (paid subscription required) 

Myths About Cancer Care In America

(Forbes) Oct 6, 2014 - In an article titled “Five Myths about Cancer Care in America” coming out in the policy journal Health Affairs today, Dana Goldman* and I take on five common misperceptions in the policy community about cancer care in the US today. Below I discuss some of the evidence and arguments contained in that piece.
read article 

Cancer Medicine: New, Improved, Expensive and Exploited?

(University of Chicago Medicine) Oct 6, 2014 - Two studies published in the October issue of Health Affairs by a University of Chicago health economist examine spending on oral anti-cancer drugs as well as a federal program designed to help the poor, which may instead helps hospitals boost profits.
read press release 

Bio-Path Holdings Successfully Completes Cohort 6 of Phase I Clinical Trial Evaluating Liposomal Grb-2 in Blood Cancers

(Yahoo! Finance) Oct 7, 2014 - Bio-Path Holdings, Inc. today announced that it has successfully completed Cohort 6 of its Phase I clinical trial evaluating lead compound, Liposomal Grb-2, in blood cancers. Bio-Path now plans to move the compound into Phase II clinical trials.
read article 

Cavion and Yale University Announce First Patient Enrolled in Phase 1b Clinical Trial in Brain Cancer

(Yahoo! Finance) Oct 7, 2014 - Cavion LLC announced today that the first patient has been enrolled in a Phase 1b clinical trial with Yale University using the company’s T-type calcium channel drug mibefradil. The trial will introduce a new therapeutic approach to patients with recurrent glioblastoma multiforme (GBM).
read article 

Thyroid Carcinoma: Biomarker Reveals Cancer Cause

(HelmholtzZentrum München [Neuherberg, Germany]) Oct 7, 2014 - The expression of the protein CLIP2* provides information on whether a papillary thyroid carcinoma was induced by radiation or had a sporadic origin.
read press release 

UConn Researchers Develop Personalized Ovarian Cancer Vaccines

(UConn blog) Oct 6, 2014 - Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer.
read article 

Blood Levels of Vitamin D May Affect Liver Cancer Prognosis

(Wiley) Oct 6, 2014 - Vitamin D deficiency is linked with advanced stages of liver cancer and may be an indicator of a poor prognosis.
read corporate press release 

Drug-Loaded Beads May Help Treat Liver Cancer

(Wiley) Oct 6, 2014 - A new phase 1 safety trial has demonstrated that idarubicin-loaded beads are well tolerated by patients but are toxic to liver cancer cells.
read corporate press release 

Most Liver Cancer Patients Do not Receive Proper Care

(Wiley) Oct 6, 2014 - Many US patients with liver cancer—even those with early stage disease that can often be cured—do not receive treatment for their disease.
read corporate press release 

Fiber-based Laxatives Linked to Decreased Risk of Colorectal Cancer: Study

(Fred Hutchinson) Oct 6, 2014 - A large, prospective study involving more than 75,000 adults in western Washington has found that frequent use of fiber-based laxatives is associated with a decreased risk of colorectal cancer while the use of non-fiber laxatives is linked to significantly increased risk of the disease.
read press release 

One in Three People with Cancer Has Anxiety or Other Mental Health Challenges

(ASCO) Oct 6, 2014 - Researchers in Germany report that nearly a third of more than 2,100 patients with cancer interviewed at inpatient and outpatient care centers experienced a clinically meaningful level of mental or emotional distress that meets the strict diagnostic criteria for mental disorders including anxiety, depressive and adjustment disorders during the prior four weeks.
read press release